Secura Drug Patent Portfolio
Secura owns 2 orange book drugs protected by 11 US patents Given below is the list of Secura's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12213983 | Treatment of cancers using PI3 kinase isoform modulators | 26 Apr, 2035 | Active |
| USRE46621 | Processes for preparing isoquinolinones and solid forms of isoquinolinones | 17 May, 2032 | Active |
| US11312718 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one | 10 Jan, 2032 | Active |
| US9840505 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof | 10 Jan, 2032 | Active |
| US8193182 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | 13 Feb, 2030 | Active |
| US9216982 | Certain chemical entities, compositions and methods | 05 Jan, 2029 | Active |
| US8883842 | Use of HDAC inhibitors for the treatment of myeloma | 13 Jun, 2028 | Active |
| US7989494 | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | 17 Jan, 2028 | Active |
| US6833384 | Deacetylase inhibitors | 30 Sep, 2021 | Expired |
| US6552065 | Deacetylase inhibitors | 31 Aug, 2021 | Expired |
| US7067551 | Deacetylase inhibitors | 31 Aug, 2021 | Expired |
Latest Legal Activities on Secura's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Secura.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eCofC Notification | 12 Aug, 2025 | US12213983 |
| Mail Patent eCofC Notification | 12 Aug, 2025 | US12213983 |
| Recordation of Patent eCertificate of Correction | 12 Aug, 2025 | US12213983 |
| Email Notification | 12 Aug, 2025 | US12213983 |
| Post Issue Communication - Certificate of Correction | 21 Jul, 2025 | US12213983 |
| Email Notification | 19 Jul, 2025 | US12213983 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 18 Jul, 2025 | US12213983 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 18 Jul, 2025 | US12213983 |
| Adjustment of PTA Calculation by PTO | 17 Jul, 2025 | US12213983 |
| Pet Dec Routed to Certificate of Corrections Branch | 17 Jul, 2025 | US12213983 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 17 Jul, 2025 | US12213983 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jun, 2025 | US9840505 |
| Petition Entered | 02 May, 2025 | US12213983 |
| Notice of Final Determination -Eligible | 27 Mar, 2025 | US8193182 |
| Email Notification | 04 Feb, 2025 | US12213983 |
Secura Drug Patents' Oppositions Filed in EPO
Secura drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 17, 2016, by Generics [Uk] Limited. This opposition was filed on patent number EP06789025A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP06789025A | Mar, 2016 | Generics [UK] Limited | Opposition rejected |
Secura's Family Patents
Secura Drug List
Given below is the complete list of Secura's drugs and the patents protecting them.
1. Copiktra
Copiktra is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12213983 | Treatment of cancers using PI3 kinase isoform modulators |
26 Apr, 2035
(9 years from now)
| Active |
| USRE46621 | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
17 May, 2032
(6 years from now)
| Active |
| US11312718 | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
10 Jan, 2032
(5 years from now)
| Active |
| US9840505 | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
10 Jan, 2032
(5 years from now)
| Active |
| US8193182 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
13 Feb, 2030
(3 years from now)
| Active |
| US9216982 | Certain chemical entities, compositions and methods |
05 Jan, 2029
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Copiktra's drug page
2. Farydak
Farydak is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8883842 | Use of HDAC inhibitors for the treatment of myeloma |
13 Jun, 2028
(2 years from now)
| Active |
| US7989494 | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
17 Jan, 2028
(1 year, 9 months from now)
| Active |
| US6833384 | Deacetylase inhibitors |
30 Sep, 2021
(4 years ago)
| Expired |
| US6552065 | Deacetylase inhibitors |
31 Aug, 2021
(4 years ago)
| Expired |
| US7067551 | Deacetylase inhibitors |
31 Aug, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Farydak's drug page